AA
MBX

ALPS Advisors’s MBX Biosciences MBX Stock Holding History

ALPS Advisors’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.65M Buy
48,012
+11,462
+31% +$400K 0.01% 442
2026
Q1 		$1.09M Sell
36,550
-322
-0.9% -$10.9K 0.01% 574
2025
Q4 		$1.16M Buy
36,872
+20,032
+119% +$486K 0.01% 509
2025
Q3 		$295K Sell
16,840
-1,208
-7% -$16.2K ﹤0.01% 988
2025
Q2 		$206K Sell
18,048
-7,986
-31% -$81.4K ﹤0.01% 1004
2025
Q1 		$192K Sell
26,034
-986
-4% -$10.4K ﹤0.01% 963
2024
Q4 		$498K Buy
+27,020
New +$576K ﹤0.01% 604

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

ALPS Advisors's MBX Position: Q2 2026 in Review

ALPS Advisors increased its MBX Biosciences (MBX) stake by 31% in Q2 2026, buying an estimated $400K and bringing the position to 48,012 shares worth $2.65M. The position accounts for 0.01% of the portfolio, ranked #442.

ALPS Advisors first reported a position in MBX in Q4 2024 and has held it in 7 quarters since. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • ALPS Advisors held 48,012 shares of MBX Biosciences worth $2.65M as of Q2 2026.
  • ALPS Advisors bought 11,462 MBX Biosciences shares in Q2 2026, an estimated $400K.
  • MBX Biosciences made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #442 holding.
  • ALPS Advisors first reported a position in MBX Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.